# A Study of MK0217A and Dietary Supplement in Men and Postmenopausal Women With Osteoporosis (0217A-227)

> **NCT00092079** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 652 (actual)

## Conditions studied

- Osteoporosis
- Vitamin D Deficiency

## Interventions

- **DRUG:** MK0217A, alendronate sodium (+) cholecalciferol / Duration of Treatment: 24 weeks

## Key facts

- **NCT ID:** NCT00092079
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-01
- **Primary completion:** 2004-11
- **Final completion:** 2004-11
- **Target enrollment:** 652 (ACTUAL)
- **Last updated:** 2014-11-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00092079

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00092079, "A Study of MK0217A and Dietary Supplement in Men and Postmenopausal Women With Osteoporosis (0217A-227)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00092079. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*